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OBJECTIVES We sought to study the effect of early infusion of abciximab on coronary patency before
primary angioplasty in patients with acute myocardial infarction.
BACKGROUND Glycoprotein IIb/IIIa antagonists have proved to be effective in reducing ischemic events
associated with coronary angioplasty. The present study explores whether abciximab alone,
without administration of thrombolytic therapy, may induce reperfusion in patients with
acute myocardial infarction.
METHODS In the Glycoprotein Receptor Antagonist Patency Evaluation pilot study 60 patients with less
than 6 h signs and symptoms of acute myocardial infarction eligible for primary angioplasty
received in the emergency room a bolus of abciximab 250 mg/kg followed by a 12-h infusion
of 10 mg/min. All patients were also treated with an oral dose of 160 mg aspirin and 5,000
IU of heparin intravenously. As soon as possible a diagnostic angiography was performed to
evaluate the patency of the infarct-related artery.
RESULTS The median time between onset of symptoms and the administration of the abciximab bolus
was 150 min (range 45 to 345), and the median time between abciximab bolus and first
contrast injection in the infarct-related artery was 45 min (range 10 to 150). In 24 patients
(40%, 95% confidence interval 28% to 52%) Thrombolysis in Myocardial Infarction (TIMI)
flow grade 2 or 3 was observed at a median time of 45 min (range 10 to 150) after abciximab
bolus; TIMI flow grade 3 was observed in 11 patients (18%, 95% confidence interval 9% to
28%). There was no difference in percentage of TIMI flow grade 2 or 3 between patients who
received abciximab within 2.5 h after onset of symptoms or thereafter.
CONCLUSIONS Abciximab therapy given in the emergency room in patients awaiting primary angioplasty is
associated with full reperfusion (TIMI flow grade 3) in about 20% and with TIMI flow grade
2 or 3 in about 40% of the patients at a median time of 45 min. These figures are higher than
those in primary angioplasty trials without such pretreatment. Randomized controlled trials
of very early infusion of abciximab, either prehospital or in-hospital, in patients eligible for
angioplasty are warranted. (J Am Coll Cardiol 1999;33:1528–32) © 1999 by the American
College of Cardiology
Early reperfuion of the occluded coronary artery is the aim
of treatment in patients with acute myocardial infarction.
Either pharmacologic therapy (1–3) with thrombolytic
drugs or mechanical treatment with primary coronary an-
gioplasty (4–6) can be used. Thrombolytic therapy has the
disadvantages of bleeding complications, thrombin genera-
tion and partial efficacy. The results of routine coronary
angioplasty after thrombolysis are disappointing (7). Pri-
mary angioplasty can achieve patency in over 90% of the
patients, but has logistic limitations including the inherent
time delay, which may exceed 100 min even in angioplasty-
dedicated centers. During this “door-to-balloon time” usu-
ally aspirin, nitroglycerin and sometimes low dose heparin
are given, but specific reperfusion therapy is usually avoided,
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since its use in connection with angioplasty is associated
with an increased complication rate. Recently, high dose
bolus heparin has been shown to improve patency before
primary angioplasty (8,9), but the safety and efficacy of high
dose bolus heparin need confirmation.
Glycoprotein IIb/IIIa receptor antagonists given in pa-
tients undergoing coronary angioplasty have shown a ben-
eficial effect in reducing ischemic events. Furthermore,
patients with acute coronary syndromes treated with glyco-
protein antagonists showed a better outcome compared with
standard therapy (10–14). These studies showed that gly-
coprotein IIb/IIIa antagonists can safely be given intrave-
nously, although they are associated with a higher bleeding
risk (14).
At this moment there is limited information available
about the effects of glycoprotein receptor antagonists on
patency of the infarct-related artery in acute myocardial
infarction. Recently, Gold et al. (15) showed a high infarct-
related artery patency rate 10 min after a single dose of
abciximab given intravenously in addition to aspirin and
heparin. The drug was given in the catheterization labora-
tory without thrombolytic therapy.
The purpose of the present pilot study was to determine
whether abciximab given to patients awaiting primary an-
gioplasty for acute myocardial infarction would be adequate
to establish coronary patency in the absence of thrombolytic
therapy. We selected patients in the emergency room who
were eligible for primary angioplasty and treated them
during the delay period until the actual performance of the
procedure.
METHODS
Patients of 80 years of age or less with signs and symptoms
of a large acute transmural myocardial infarction with onset
of symptoms within 6 h and a sum of ST-segment elevation
of 10 mm or more were eligible for entry in this study.
Patients with a contraindication to antiplatelet therapy,
signs of active bleeding or inability to give informed consent
were excluded. The patients included were recruited in five
hospitals in The Netherlands and two in Sweden.
After the decision to perform primary angioplasty, all
patients were treated with an oral dose of aspirin (160 mg)
and heparin 5,000 IU intravenously in the emergency room.
After oral informed consent they also received a bolus of
abciximab of 250 mg/kg followed by 10 mg/min infusion. As
soon as possible patients were transported to the catheter-
ization laboratory where coronary angiography was per-
formed. The end point in this study was patency of the
infarct-related artery at first contrast injection.
Patency of the infarct-related artery was scored according
to the Thrombolysis in Myocardial Infarction (TIMI) flow
grading scale (16) by two independent experienced investi-
gators at the core lab (Cardialysis, Rotterdam, The Neth-
erlands). Further treatment regimen was left at the discre-
tion of the attending physician.
RESULTS
Between November 1996 and July 1997 60 patients were
enrolled. The baseline characteristics of the patients are
given in Table 1.
There was a relatively wide range in the time interval
between the onset of symptoms and the bolus abciximab
therapy. Also the time between abciximab bolus and first
contrast injection in the infarct-related artery varied consid-
erably and could take up to 150 min.
The culprit lesion was located in the right coronary artery
in 22 patients, in the left anterior descending coronary artery
in 29 patients and in the left circumflex artery in 6 patients.
In one patient the left main artery was subtotally occluded,
and in two patients the infarct-related vessel was a venous
bypass graft. In 36 patients (60%) TIMI flow grade 0 and 1
at first contrast injection was seen. Thrombolysis in Myo-
cardial Infarction flow grade 3 was seen in 11 patients (18%,
95% confidence interval 9% to 28%) and TIMI flow grade
2 or 3 was seen in 24 patients (40%, 95% confidence interval
28% to 52%).
There was no difference in percentage of TIMI flow
grade 2 and 3 between patients who received abciximab
within 2.5 h after onset of symptoms (n 5 30) or thereafter
(n 5 30), as depicted in Figure 1. There was also no
difference in percentage of TIMI flow grade 2 and 3
between patients who underwent angiography within
45 min after the initiation of the abciximab administration
and those who did thereafter.
None of the 60 patients in the trial had major hemor-
rhage leading to the need for blood transfusion. There were
no in-hospital strokes, and no patient died.
Abbreviations and Acronyms
GRAPE 5 Glycoprotein Receptor Antagonist Patency
Evaluation
GUSTO 5 Global Utilization of Streptokinase and
Tissue Plasminogen Activator in Occluded
Arteries
TIMI 5 Thrombolysis in Myocardial Infarction
Table 1. Baseline Characteristics of the Patients in the GRAPE
Pilot Study
Number of patients (n) 60
Age (years, median, range) 63 (31 to 76)
Male (%) 70
Time from onset of symptoms to treatment
(min, median, range)
150 (35 to 345)
Time from abciximab bolus to first contrast
injection (min, median, range)
45 (10 to 150)
GRAPE 5 Glycoprotein Receptor Antagonist Patency Evaluation.
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DISCUSSION
Sofar, the Glycoprotein Receptor Antagonist Patency Eval-
uation (GRAPE) pilot trial is the largest to study the effect
of abciximab on coronary patency in patients eligible for
primary angioplasty for acute myocardial infarction. Fur-
thermore, it is the largest study on emergency room initia-
tion of glycoprotein receptor antagonist therapy in acute
coronary syndromes.
In the GRAPE pilot study a positive effect of abciximab
bolus given in the emergency room on early infarct-related
artery patency became apparent with a TIMI flow grade 2 or
3 in 40% of patients at 45 min. Usually infarct-related artery
patency (TIMI flow grade 2 or 3) in patients treated only
with low dose heparin bolus and aspirin is poor and does not
exceed 25% after 90 min (5,16,17). In our trial the patients
received the abciximab bolus and started with the infusion
therapy during the waiting time for the transfer from the
emergency room to the catheterization laboratory.
Other observations. Our results are consistent with those
of two other smaller patency studies on emergency room
initiation of glycoprotein antagonists in patients with acute
transmural myocardial infarction. In the reported, but not
yet published Strategies for Patency Enhancement in the
Emergency Department and TIMI-14A trials (18,19), ab-
ciximab bolus and infusion was initiated in the emergency
room. Its effect on TIMI flow grade 3 evaluated at 60 and
90 min respectively is larger than in our trial, where the
median time to angiography was only 45 min. Taken
together, the three early abciximab trials, where TIMI flow
grading was read in core labs, show significantly more TIMI
flow grade 3 preangioplasty than the angioplasty arm of the
Global Utilization of Streptokinase and Tissue Plasminogen
Activator in Occluded Arteries (GUSTO)-IIb Angioplasty
Substudy (17), the largest trial evaluating TIMI flow grades
preangioplasty by core lab reading (chi-square test, Fig. 2).
The same low percentage (,10%) of spontaneous TIMI
flow grade 3 was found in the classic TIMI-1 (16) study and
the control arms of the high dose heparin trials (8,9).
Interestingly, in Figure 2 there seems to be a trend toward
time dependency of abciximab in achieving TIMI flow
grade 3.
Figure 1. Relation between the time interval symptom onset–
abciximab and the patency of the infarct-related artery at angiog-
raphy. Black bars: Thrombolysis in Myocardial Infarction (TIMI)
flow grade 2. Gray bars: TIMI flow grade 3.
Figure 2. Preangioplasty Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 (with 95% confidence interval) in the reported
emergency room initiated abciximab patency trials, each separately and together, compared with that preangioplasty in the angioplasty arm
of the GUSTO-IIb Angioplasty Substudy (17). angio 5 angiography; GRAPE 5 Glycoprotein Receptor Antagonist Patency Evaluation;
SPEED 5 Strategies for Patency Enhancement in the Emergency Department study.
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Mechanism of reperfusion. Possibly, the combination of
endogenous tissue plasminogen activator and the adminis-
tered abciximab induces reperfusion. This may be explained
by the anatomy of the occluding thrombus. Plaque rupture
leads to a release of highly thrombogenic factors which
activate platelets and the coagulation cascade. Platelet acti-
vation consists of presenting the glycoprotein IIb/IIIa re-
ceptor on the platelet surface at which fibrinogen can bind.
The formation of fibrinogen dimers results in further
aggregation (20,21). A fresh clot probably contains a large
amount of platelets together with fibrin (white clot). As
time passes by the clot will contain more and more fibrin,
erythrocytes and white blood cells, and will become more
stable (red clot). Thrombolytic agents are effective in dis-
solving fibrin and therefore they may achieve reperfusion.
The remaining white clot and the ruptured vessel wall can
give cause to early reocclusion. Antiplatelet therapy may
positively influence this subtle balance of early reperfusion/
reocclusion. This was already suggested by the aspirin
results of the ISIS-2 trial (22). In our patient group
thrombolytic therapy was not given, and the lytic effects we
observed may have come from endogenous tissue plasmin-
ogen activator, whereas abciximab protects against further
platelet aggregation and possibly reocclusion. We could not
detect a temporal relationship between the age of the clot
and the reperfusion efficacy of abciximab, as was found in
the much smaller study of Gold (23). In that observation
glycoprotein receptor antagonist treatment in the catheter-
ization laboratory in 24 patients undergoing primary percu-
taneous transluminal coronary angioplasty was more effec-
tive in patients with a short time interval between symptom
onset and the administration of abciximab. Interestingly the
same phenomenon was observed with high dose bolus
heparin in the HEAP pilot study (8). It should be noted
that in the GRAPE pilot study patients were treated much
earlier than in Gold’s study and in about the same time
window as the HEAP pilot trial. In the GRAPE pilot trial
there was no relationship between the time from initiation
of therapy and patency, which is usually seen in thrombol-
ysis. In Gold’s experimental and clinical study (15) it was
suggested that abciximab induces reperfusion within
10 min. In our study vessels may have reoccluded in the
meantime, which took an average of about 45 min. Given
the very strong antiplatelet action of abciximab this is
unlikely.
Further studies. Recently, a randomized placebo-
controlled trial of abciximab given in the catheterization
laboratory to 483 patients undergoing primary angioplasty
for acute myocardial infarction was reported. The RAPPORT
study showed a 36% reduction of death, reinfarction and
revascularization (p 5 0.11) in the patients receiving abcix-
imab in the catheterization laboratory (24).
A combination of a reduced dose of thrombolytics with a
glycoprotein IIb/IIIa receptor antagonist may improve the
early patency rate further (18,19). The safety and efficacy of
this strategy is currently being tested in the large
GUSTO-IV and the TIMI-14 studies. Clearly, agents
other than thrombolytics may induce reperfusion in some
patients. Studies other than that of Gold (15) and our own
indicate that nonthrombolytic reperfusion is possible; high
dose heparin bolus may also have the same properties (8,9).
Study limitations. The most important limitation is the
absence of a parallel control group. Furthermore, there is no
angiographic follow-up after the moment of first contrast
injection. The total number of patients is small with regard
to safety and efficacy, and therefore further investigations
are needed.
Conclusions. Thus, abciximab given in the emergency
room to patients with acute myocardial infarction awaiting
primary angioplasty is associated with TIMI flow grade 3 in
about 20% and TIMI flow grade 2 or 3 in 40% of the cases
at a median time of 45 min after initiation of therapy. This
result is much better than in the primary angioplasty studies
without abciximab pretreatment. However, the favorable
angiographic outcome of our trial and two smaller observa-
tions should be tested in a randomized controlled trial,
before this strategy can be implemented in the emergency
room or the prehospital phase. Perhaps a combination of
low dose thrombolysis and glycoprotein IIb/IIIa antagonist
may improve these results further, which issue is currently
under investigation.
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